REVIVA PHARMACEUTICALS HOLDINGS

Company snapshot

NASDAQ: RVPH Reviva Pharmaceuticals, Inc., (Reviva) headquartered in Santa Clara, California, is a publicly traded, late-stage clinical development pharmaceutical company. Reviva is developing a portfolio of internally discovered next generation innovative therapies using chemical genomic driven approaches and proprietary technologies that addresses unmet medical needs in the areas of central nerv

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 28 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for REVIVA PHARMACEUTICALS HOLDINGS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for REVIVA PHARMACEUTICALS HOLDINGS.

1. Jun 5, 2026 Clinical update

   Lipoaspiration — Phase 1

2. May 26, 2026 Clinical update

   RP5063 — Phase 2

3. May 23, 2026 Clinical update

   Brilaroxazine — Phase 3

4. Aug 6, 2024 Patent grant

   Methods for treating pulmonary fibrosis

5. Oct 15, 2019 Patent grant

   Methods for treating pulmonary hypertension

View all clinical trial activity →

• What is REVIVA PHARMACEUTICALS HOLDINGS?

  Reviva Pharmaceuticals is a pharma organization headquartered in Cupertino, USA. It trades on NYSE under ticker RVPH. Primary therapeutic focus areas include Acute Schizophrenia, Schizophrenia, Hereditary Corneal Dystrophy. NovaPharmaNews links 3 clinical program(s), 0 drug profi

• Is REVIVA PHARMACEUTICALS HOLDINGS publicly traded?

  Yes. REVIVA PHARMACEUTICALS HOLDINGS is listed with ticker RVPH on NYSE per SEC EDGAR records linked on this profile.

• What drugs does REVIVA PHARMACEUTICALS HOLDINGS develop or market?

  We link 1 drug profile(s) where REVIVA PHARMACEUTICALS HOLDINGS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/reviva-pharmaceuticals-holdings-inc#company-drugs.

• What are the latest developments for REVIVA PHARMACEUTICALS HOLDINGS?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does REVIVA PHARMACEUTICALS HOLDINGS focus on?

  REVIVA PHARMACEUTICALS HOLDINGS focuses on Acute Schizophrenia, Schizophrenia, Hereditary Corneal Dystrophy based on our analysis of their pipeline programs and drug development activities.